For the quarter ending 2025-09-30, NTLA has $925,275K in assets. $176,853K in debts. $193,389K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 193,389 | 156,172 | ||
| Marketable securities | 317,655 | 303,479 | ||
| Accounts receivable | 11,050 | 11,353 | ||
| Prepaid expenses and other current assets | 59,847 | 24,941 | ||
| Total current assets | 581,941 | 495,945 | ||
| Marketable securities - noncurrent | 158,814 | 170,855 | ||
| Property and equipment, net | 20,421 | 22,806 | ||
| Operating lease right-of-use assets | 117,883 | 129,045 | ||
| Investments and other assets | 46,216 | 80,243 | ||
| Total assets | 925,275 | 898,894 | ||
| Accounts payable | 13,260 | 9,802 | ||
| Accrued expenses | 40,841 | 41,553 | ||
| Current portion of operating lease liability | 27,378 | 26,990 | ||
| Current portion of deferred revenue | 12,247 | 17,154 | ||
| Total current liabilities | 93,726 | 95,499 | ||
| Deferred revenue, net of current portion | 12,539 | 12,539 | ||
| Long-term operating lease liability | 70,588 | 75,601 | ||
| Total liabilities | 176,853 | 183,639 | ||
| Common stock, 0.0001 par value 240,000,000 shares authorized at september 30, 2025 and december 31, 2024 115,787,285 and 102,029,594 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 12 | 10 | ||
| Additional paid-in capital | 3,241,728 | 3,107,576 | ||
| Accumulated other comprehensive income | 990 | 653 | ||
| Accumulated deficit | -2,494,308 | -2,392,984 | ||
| Total stockholders equity | 748,422 | 715,255 | ||
| Total liabilities and stockholders' equity | 925,275 | 898,894 | ||
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)